A placebo-controlled trial has shown that the oral AKT inhibitor engasertib could reduce the frequency and duration of ...

A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for ...

Hereditary hemorrhagic telangiectasia (HHT) can cause recurrent, severe epistaxis, as well as anemia and reduced quality of ...

Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...

Data demonstrate that ATV-1601, a selective allosteric inhibitor of AKT1 E17K, provides enhanced target inhibition, superior efficacy and improved tolerability compared to pan-AKT inhibitors in ...

SAN ANTONIO -- Addition of an investigational AKT inhibitor to standard fulvestrant (Faslodex) doubled median progression-free survival (PFS) in the second-line setting for patients with hormone ...

NB: this presentation will be the subject of an embargoed news briefing by co-author Dr Kevin Kalinsky on Monday 24 October at 17.00 hrs CEST. Barcelona, Spain: In a trial matching new treatments to ...

Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719. This is an ...

In a trial matching new treatments to cancer patients based on the genetic make-up of their tumors, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumors shrink. This ...